Clinical Trials
6
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
2011
Completed
6
100.0%
No approval data available
- Ultimovacs ASA reported active enrollment in the DVO trial for BRCA-negative ovarian cancer, with results expected in the first half of 2025. - The company halted recruitment for the LV trial in non-small cell lung cancer due to slow enrollment, with results anticipated in early 2025. - Ultimovacs is advancing a novel drug conjugation technology platform, with updates slated for the end of 2024, aiming to broaden its vaccine pipeline. - Financial strategies, including downsizing, have extended the company’s cash runway through the first quarter of 2026.
- FDA has expanded the approval of pembrolizumab (Keytruda) in combination with pemetrexed and cisplatin for previously untreated advanced/metastatic malignant pleural mesothelioma. - Patritumab deruxtecan demonstrated a statistically significant improvement in progression-free survival versus doublet chemotherapy in patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer. - A novel three-drug regimen yielded an 80% response rate in a small study of patients with advanced chronic myelogenous leukemia or high-risk acute myeloid leukemia.
